In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS)

Leukemia

Volumn 11, Issue 10, 1997, Pages 1726-1731

  Sarina, B ^a   Cortelezzi, A ^a,b   Cattaneo, C ^a   Pomati, M ^a   Silvestris, I ^a   Di Stefano, M ^a   Lambertenghi Deliliers, D ^a   Hu, C ^a   Monza, M ^a   Maiolo, A T ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Clonogenic activity; Interleukin 12; Interleukin 2; Myelodysplastic syndromes; NK activity

Indexed keywords

CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 2;

ARTICLE; BONE MARROW; CLINICAL ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE; MONONUCLEAR CELL; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 16944364153     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400813     Document Type: Article

References (14)

1. Bennet GM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C. Proposal for the classification of myelodysplastic syndrome. Br J Haematol 1982; 51: 189-199.
2. Weimar IS, Bourhis JH, De Gast GC, Gerritsen WR. Clonality in MDS. Leuk Lymphoma 1994; 13: 215-221.
3. Kouides PA, Bennet JM. Morphology and classification of myelodysplastic syndromes. Hematol Oncol 1992; 3: 485-499.
4. Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW. Refractory cytopenia with multilineage dysplasia: further classification of an 'unclassifiable' myelodysplastic syndrome. Leukemia 1996; 10: 20-26.
5. Lai JL, Preudhomme C, Zandecki M, Flactif M, Vanrumbeke M, Lepelley P, Wattel E, Fenaux P. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopioesis and a high incidence of p53 mutations. Leukemia 1995; 9: 370-381.
6. Morel P, Hebbar M, Lai JL, Duhamel A, Preudhomme C, Wattel E, Bausters F, Fenaux P. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases. Leukemia 1993; 7: 1315-1323.
7. Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M, Yamane Y, Inazawa J, Abe T, Kashima K. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndromes. Leukemia 1994; 8: 1331-1336.
8. Preudhomme C, Vanrumbeke M, Lai JL, Lepelley P, Wattel E, Fenaux P. Inactivation of the p53 gene in leukemias and myelodysplastic syndromes (MDS) with 17p monosomy. Leukemia 1994; 8: 2241-2242.
9. Takaku S, Takaku F. Natural killer cell activity and preleukemia. Lancet 1981; 2: 1178.
10. Porzsolt F, Heimpel H. Impaired T-cell and NK-cell function in patients with preleukemia. Blut 1982; 45: 243-248.
11. Hokland P, Kerndrup G, Griffin JD, Ellegard DJ. Analysis of leukocyte differentiation in blood and in bone marrow from preleukemia (refractory anemia) patients using monoclonal antibody. Blood 1986; 67: 898-902.
12. Ogata K, Fujii H, Yokose N. Defective natural killer cell-mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes. Br J Haematol 1994; 87: 396-398.
13. VanKamp H, Fibbe WE. Clonal involvement of granulocytes and monocytes, but not T and B lymphocytes and NK cells in restriction fragment lengh polymorphism and polymerase chain reaction of the phosphoglycerate kinase gene. Blood 1992; 80: 1774-1780.
14. Kobayashi M, Fitz L, Rian RY, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.